Performance of coumarin-derived dendrimer-based fluorescence-linked immunosorbent assay (FLISA) to detect malaria antigen by unknown
Yeo et al. Malaria Journal 2014, 13:266
http://www.malariajournal.com/content/13/1/266METHODOLOGY Open AccessPerformance of coumarin-derived dendrimer-based
fluorescence-linked immunosorbent assay (FLISA)
to detect malaria antigen
Seon-Ju Yeo1, Dinh Thi Huong1, Jin-Hee Han2, Jung-Yeon Kim3, Won-Ja Lee3, Ho-Joon Shin4, Eun-Taek Han2*
and Hyun Park1*Abstract
Background: Due to limitation of conventional malaria diagnostics, including microscopy, polymerase chain
reaction (PCR), and enzyme-linked immunosorbent assay (ELISA), alternative accurate diagnostics have been
demanded for improvement of sensitivity and specificity.
Methods: Serially diluted Plasmodium LDH antigens, Plasmodium falciparum-infected human red blood cells (RBC)
derived from in vitro culture or patient’s samples were used for evaluation of the performance of fluorescence-linked
immunosorbent assay (FLISA). Microscopic examination was used to determine parasite density and the performance
of FLISA was compared to ELISA. Finally, sensitivity and specificity of FLISA was determined by human specimens
infected with P. falciparum, Plasmodium vivax, Toxoplasma gondii, and amoebae.
Results: As a result of FLISA, the fluorescent intensity was highly correlated with antigen amount and FLISA was more
sensitive than ELISA. FLISA detected at least 0.01 ng/ml of pLDH antigen, which showed 1,000-fold higher sensitivity
than ELISA. In vitro-cultured P. falciparum was detected up to 20 parasite number/μL in FLISA but 5120 parasite
number/μLin sandwich ELISA. In vitro P. falciparum-infected RBC number was highly correlated with fluorescent
intensity (R2 = 0.979), showing that FLISA was reliable for detection of P. falciparum and available for quantification of
parasite numbers. Furthermore, eighteen patient samples infected with P. falciparum (n = 9) and P. vivax (n = 9) showed
100% of sensitivity (18/18). FLISA showed 96.3% of specificity (26/27) because one sample of patient blood infected
with T. gondii gave a false positive reactivity among healthy donors (n = 9), T. gondii-infected patients (n = 9), and
amoeba-infected patients (n = 9).
Conclusion: FLISA has a keen and high performance to detect malaria antigen, suggesting a potential assay as malaria
immunodiagnostic.
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Five human infectious malarias, including Plasmodium
falciparum, Plasmodium vivax, Plasmodium ovale, Plas-
modium malariae, and Plasmodium knowlesi, remain a
serious health issue and are widespread in developing
countries, continuing to cause about 219 million cases
and one million deaths annually [1]. National malaria
mortality rates are, however, particularly difficult to assess
reliably and are underestimated in some important en-
demic areas due to misunderstanding malaria infection
[2-4]. Therefore, the establishment of accurate diagnostics
of malaria based on quantification of malaria parasite
number with high sensitivity and specificity is the top
priority for the management of malaria.
As a gold standard of malaria diagnostics, thick and thin
blood smears are reliable but it was claimed that in the case
of low parasitaemia, aggregation in a specific area of the
smear was noticed and blood smearing was less sensitive
than immunodiagnostics and PCR methods [5,6]. As an al-
ternative quantitative diagnosis of malaria, over the last few
decades, numerous polymerase chain reactions (PCR)-based
diagnostic tests targeting RNA or DNA have been developed
to confirm the malaria infection in addition to microscopic
observation [7-9]. Quantification of malaria infectious para-
site numbers in patients with only RNA or DNA copy num-
bers has been implemented but the requirement of
equipped laboratory facilities presents an obstacle to applica-
tion to a field setting [10]. Due to the limitation of PCR, dif-
ferent immunological assays that use antibodies to detect
parasites have been developed with greater potential for
adaption to field application than previous approaches, even
though immune assays provide sensitivity issues [11]. There-
fore, immunological assays have become the basis of most
commercial diagnostic test kits, with most interest focused
on the use of monoclonal antibodies (mAbs). Using mAbs,
enzyme-linked immunosorbent assay (ELISA) method and
fluorescence-linked immunosorbent assay (FLISA) have
established significant diagnostic biomarkers [12,13]. Result-
ing devices for the diagnosis of malaria based on malaria-
specific antigens, such as histidine-rich protein 2 (HRP2)
and lactate dehydrogenase (LDH), have been developed as
alternative diagnostics to microscopy and PCR [14].
Microscopy has often been the routine diagnostic tech-
nology available in developing countries. However, it has
been considered to show variable sensitivity depending on
expertise of microscopist [15]. Despite continuous applica-
tion as key diagnostic tests, microscopy techniques have
limitations as universal or targeted donor screening tests
due to lack of sensitivity at low parasitaemia [16]. As a
higher throughput method of malaria diagnosis, ELISA is
suitable for epidemiological surveys [12].
Previously, performance of two monoclonal antibodies
(D2H and D7E) targeting conserved 31 amino acids of
Plasmodium LDH was shown to be potential to be usefulfor malaria diagnostics [17]. Besides, light-emitting diode
(LED)-based novel organic fluorophore, coumarin-derived
dendrimer was developed for malaria diagnostics [13]. As a
light source of biosensor, LED has the advantage, because
laser diode has various limitations such as expense, difficult
operation, limited emission wavelength selections, and a
short lifetime [13]. Therefore, development of LED light
based diagnostics has advantage as further diagnostics. In
this study, the enhanced coumarin-derived dendrimer-
based malarial FLISA assay with novel monoclonal anti-
bodies (D2H and D7E) was compared with ELISA.
Methods
In vitro culture and determination of parasitaemia
Plasmodium falciparum FCR-3 (ATCC 50005) were pur-
chased from ATCC (Manassas, VA, USA) and strains
used in this study were kept in −80°C as frozen stocks.
Plasmodium falciparum was cultured by standard pro-
cedure as described previously [18], using a 5% haemato-
crit of type O-positive human red erythrocytes suspended
in RPMI 1640 medium with 5% NaHCO3, 0.5% Albumax,
25 μg/mL gentamicin and supplemented with heat-
inactivated 10% type O-positive human serum. The six-
well plates were placed in an incubator (5% CO2, 5% O2,
and 90% N2 atmosphere) at 37°C, and the medium was
changed daily at least 5% parasitaemia. Blood smears were
stained with Giemsa for counting parasite numbers with
microscopy under 1,000 ×magnifications. Parasite density
was determined as a percentage of infected erythrocytes in
fields of total 500 erythrocytes in the study. Animal exper-
iments were performed at the experimental protocol,
which was approved by the Animal Care and Use Com-
mittee at Wonkwang University.
Purification of coumarin-derived dendrimer-or
horseradish peroxidase (HRP)-bioconjugates
Subcloned cells (D7E or D2H) secreting pLDH were kindly
provided by Professor Ho-Joon Shin in Ajou University,
which were used in the previous report [17]. To obtain
mouse ascitic fluid, 1 × 107 cells were injected in incom-
plete Freund's adjuvant-primed ICR mice. Ascitic fluids
harvested were further processed for purification of anti-
bodies by protein A agarose 4B column (Incospharm,
Korea) according to manufacturer’s instruction.
Purified D2H (1 mg/ml) were gently mixed with conju-
gation buffer (0.1 M NaHCO3, pH 8.5) for 30 min at room
temperature (RT) with gentle rotation. After coumarin-
derived dendrimer (a kind donation of Dr Hak Sung Kim,
Wonkwang University, Korea) was dissolved in DMSO
(1 mg/ml), antibody (D7E) in conjugated buffer was incu-
bated with 6 moles per mole of antibody for overnight at
4°C. Then the mixture was filtered by using desalting col-
umn (Thermo Scientific™ Zeba™ Spin Desalting columns)
to remove free coumarin-derived dendrimer. Coumarin-
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fugation at 1,000 × g for 2 min at 4°C.
D2H (1 mg/ml) was conjugated with horseradish pero-
xidase (HRP) in EZ-Link™ Plus Activated Peroxidase
(Thermo Scientific, Rockford, IL, USA) according to manu-
facturer’s instructions. Briefly, 1 mg/ml of D2H in
carbonate-bicarbonate buffer (pH 9.4) were reacted with
1 mg of lyophilized peroxidase at RT for one hour. After
additional reaction with 10 μL of sodium cyanoborohydride
for 15 min at RT, reaction stopped by 20 μL of quenching
buffer for 15 min at RT. The HRP bioconjugates were
further purified with conjugate purification kit (Thermo
Scientific, Rockford, IL, USA) to remove unbound HRP.
Fluorescence-linked immunosorbent assay (FLISA)
FLISA were performed as previously described [13]. Plas-
modium falciparum and Plasmodium vivax recombinant
LDH (rLDH) were purchased from C&K Bio ResourceLE
– Plasmodium rLDH antigens




Figure 1 Schematic illustration of FLISA with novel monoclonal antib
FLISA consists of a capture antibody, analytes and coumarin-derived dendr
overnight. Meanwhile, amine group of mAbs react with N-hydroxysuccinim
amide bonds upon release of NHS. After washing, LDHs from analytes were
LED induced excitation of coumarin-derived dendrimer at 460 nm and emInc, Korea. Briefly, 1 μg/well D7E were prepared for coat-
ing a black 96-well microtitre plate (Greiner, Germany)
overnight and next day, plate was blocked with 2% casein-
based blocking buffer at 37°C. After two hours, plate was
washed with 200 μL of phosphate buffered saline with
0.05% Tween 20 (PBS-T, pH 7.4) and 100 μL of sample
were added to each well and incubated at 37°C. After two
hours, plate was washed with 200 μL of PBS-T. Finally,
200 μL of coumarin-derived dendrimer-conjugated D2H
was added to detect antigens for one hour. Stringent
washing with PBS-T was performed six times to remove
unbound antibodies and 100 μL of PBS was added to
each well to measure the fluorescence. Fluorescence
with 460 nm excitation and 560 nm emission was mea-
sured using an Infinite F200 microplate reader (TECAN,
Männedorf, Switzerland). Relative fluorescence was deter-
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ission at 590 nm were detected.
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Polystyrene, 96-well plate (NUNC, Pasadena, Texas, USA)
was coated with 100 μL (10 μg/mL) of D7E in coating buf-
fer (50 mM bicarbonate/carbonate coating buffer, pH 9.6)
and stored in an incubator overnight at 4°C. After incuba-
tion, the plate well was washed four times with 200 μL of
PBS-T and blocked with 1% casein-based blocking buffer
at 37°C for two hours. After washing with PBS-T buffer
twice, differently diluted analytes were allowed to each
well. The 100 uL of HRP conjugates D2H (2 ug/ml) was
applied to each well at 27°C for one hour. After washing
with PBS-T five times, plates were filled with 100 μL of
3,3’,5,5;-tetra methyl benzidine (TMB) substrate solution
(Invitrogen, Camarillo, CA, USA) in the dark for 30 min,
following stopping with additional 100 μL of sulphuric
acid (0.5 M) per well. Optical density (OD) was measured
by a microplate reader at 450 nm. Data were expressed as
mean ± standard deviation.
Ethical considerations
Professor Tai-Soon Yong (Yonsei University, College of
Medicine, Seoul, Korea) kindly provided amoeba-infected
specimens and Professor Ho-Woo Nam (Catholic Univer-
sity, College of Medicine, Seoul, Korea) kindly provided
Toxoplasma gondii-infected samples. Malaria patient
samples were provided from professor Eun-Taek Han
(Kangwon National University, School of Medicine,
Chuncheon, Korea). The study was approved by the
Kangwon National University Hospital Institutional Re-
view Board (Approval No. 10-041-07).
Results
Coumarin-derived dendrimer was chosen as labelling fluo-
rophore, which was confirmed to have good spectroscopic
properties in previous study [13]. In this study, two newly
developed mAbs targeting pLDH were used for FLISA
instead of commercialized mAbs of pLDH, and performanceTable 1 Alignment of pLDH epitope among Plasmodium spec
Species Epitope region in LDH
P. vivax 75 FTKAPGKSDKEWNRDDLLPLNNKIMIEIGG
P. falciparum 61 FTKAPGKSDKEWNRDDLLPLNNKIMIEIGG
P. knowlesi 82 FTKAPGKSDKEWNRDDLLPLNNKIMIEIGG
P. yoelii 17XNL 82 FTKAPGKSDKEWNRDDLLPLNNKIMIEIGG
P. berghei ANKA 82 FTKAPGKSDKEWNRDDLLPLNNKIMIEIGG
P. malariae 75 FTKVPGKSDKEWNRDDLLPLNNKIMIEIGG
P. ovale 75 FTKAPGKSDKEWNRDDLLPLNNKIMIEIGG
Eimeria maxima 88 TKIPGKSDKEWSRMDLLPVNIKIMREVGG 1
Toxoplasma gondii 86 LTKVPGKSDKEWSRNDLLPFNAKIIREVA 1
Homo sapiens 98 AGARQQEGESRLNLVQRN123
Plasmodium LDH epitope (FTKAPGKSDKEWNRDDLLPLNNKIMIEIGGH) is highly conse
determined by epitope alignments across the listed in NCBI.in FLISA was defined to determine antigen-antibody reactiv-
ity. Figure 1A illustrates the schematic representations of
the conjugation reactions to understand the principle of
the coumarin-derived dendrimer-based FLISA with three
analytes (Plasmodium recombinant LDH, in vitro P. fal-
ciparum-infected human RBC, and patients bloods). N-
hydroxysuccinimide (NHS) esters of coumarin-derived
dendrimers react with primary amine groups (−NH2) of
mAbs in buffer (pH 8.5) to form stable amide bonds upon
release of NHS. Further FLISA procedure is followed on
conventional sandwich ELISA and in FLISA, fluorescence
intensity indicates the interaction between parasite antigen
and coumarin-derived dendrimer-conjugated antibody.
The wavelength of maximum absorption (usually the same
as the excitation maximum) of coumarin-derived dendri-
mer is 460 nm and excitation spectrum of a given biocon-
jugate is 590 nm [13].
Plasmodium LDH is an enzyme of glycolytic pathway of
different Plasmodium species at both the asexual and se-
xual stages and also correlated with the number of para-
sites present in the plasma of infected patients [19-21].
The LDH from P. vivax, P. malariae, and P. ovale has 87%
sequence identity with pLDH from P. falciparum [22]. In
current study, target epitope (1–31 amino acid) of Plasmo-
dium LDH were aligned in BLAST, using BLASTP 2.2.29+
program and the epitope sequence of Plasmodium LDH
shows 97-100% identities among seven Plasmodium spe-
cies [P. falciparum (GenBank accession no. AEX28368.1),
P. vivax (GenBank accession no. AAS77573.1), P. malariae
(GenBank accession no. AAS77572.1), P. ovale (GenBank
accession no. AAS77571.1), P. knowlesi (GenBank acces-
sion no. AEL88505.1), Plasmodium yoelii (GenBank acces-
sion no. XP724101.1), and Plasmodium berghei (GenBank
accession no. XP679401.1)]. In contrast, the eptitope of
Plasmodium LDHs shows 76% identities of Emeiria
maxima LDH (GenBank accession no. AAN38977.1)
and 66% of Toxoplasma gondii LDH (GenBankies
Identity GenBank accession no.
H 105 31/31(100%) AAS77573.1
H 91 31/31(100%) AEX28368.1
H 112 31/31(100%) AEL88505.1
H 112 31/31(100%) XP724101.1
H 112 31/31(100%) XP679401.1
H 105 30/31(97%) AAS77572.1




rved among seven Plasmodium spp. and the percentage of sequence identity is
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26% identities in Homo sapiens LDH (GenBank acces-
sion no. CAE11711) (Table 1). Therefore, antibodies tar-
geting this epitope may act as pan-specific anti-LDH,
which is able to react with most Plasmodium spp.
To investigate the ability of FLISA to quantify malaria











































Figure 2 Comparison of FLISA and ELISA detectability against Plasmo
generated: P. falciparum rLDH in FLISA (A), P. vivax rLDH in FLISA (B), and P
detectable but 10 ng/uL of antigen was a minimum detectable antigen levof P. falciparum- and P. vivax-recombinant LDH antigens
at six-point standard curve based on two-fold dilutions from
0.01 to 1,000 ng/mL. Well-defined linear regressions were
produced at FLISA for both P. falciparum-(R2 = 0.972) and
P. vivax (R2 = 0.967) LDH (Figure 2A and B). Plasmodium
LDH antigen was detectable up to 10 ng/mL in ELISA at
the same condition with FLISA (Figure 2C). As OD value of10 -1 10 0 10 1 10 2 10 3
R2=0.972
arum  rLDH (ng/µl)
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dium LDH. Standard curve for a detectable range of FLISA were
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Figure 3 Comparison of FLISA (A) and ELISA (B) analyses of Plasmodium falciparum-infected human red blood cells. Human bloods were
































Figure 4 FLISA performance to diagnosis malaria infection in
patient samples. P. falciparum (n = 9)- and P. vivax (n = 9)-infected
patients bloods were applied to FLISA to evaluate the sensitivity of
FLISA. As non-malaria specimens, healthy donors (n = 9), T. gondii
(n = 9)-, and amoeba (n = 9)-infected patient bloods were tested to
determine the specificity. Red dotted line indicates the cut-off value
between positive- and negative values of FLISA.
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http://www.malariajournal.com/content/13/1/2660.1 is positive, the detection threshold of FLISA is at least
1,000-fold higher than ELISA, implying that FLISA would
contribute to increase detectability of pLDH in early infec-
tion when it is hard to be detected in conventional ELISA.
Furthermore, in vitro-cultured P. falciparum was prepared
to determine FLISA performance to detect P. falciparum-in-
fected blood RBC. P. falciparum infected human RBC and
cultured for three days to induce 3.2% of parasitaemia in
1.6 × 108 total RBC. As a result of FLISA, fluorescent inten-
sity and P. falciparum density was highly correlated and reli-
able (R2 = 0.97), between 20 and 5,120 parasites (Figure 3A).
In contrast, detection threshold of ELISA was 5,120 para-
sites (Figure 3B). Therefore, FLISA would be a useful diag-
nostic assay with high detectability to quantify low number
of parasite density than ELISA.
To determine the sensitivity and specificity of FLISA, P.
falciparum (n = 9) and P. vivax (n = 9) infected patient’s
bloods were applied to FLISA and FLISA showed 100% of
sensitivity (18/18). In contrast, non-malaria disease sam-
ples among healthy donors (n = 9), T. gondii- (n = 9), and
amoeba-infected patients (n = 9) showed one false positive
reactivity with T. gondii-infected patient blood. Therefore,
specificity of FLISA was 96.3% (26/27) (Figure 4).
Conclusion
Since elimination of malaria infection by WHO, malaria
prevalence is getting low but still prevalent worldwide. In
Republic of Korea (ROK), after reemergence of malaria
near location of demilitarized zone (DMZ) in 1993, the
annual incidence has increased rapidly [23-25]. Until
2010, ten cases of transfusion-transmitted malaria have
been reported in ROK [26]. The incidence of transfusion-
transmitted malaria among people residing in endemic
areas is unknown and a substantial proportion of thepopulation in malaria-endemic countries has asymp-
tomatic parasitaemia [16]. Therefore, development of en-
hanced Plasmodium blood screening test is advocated to
prevent spread by transfusion in blood banks and in ROK,
ELISA has been developed to screen and monitor trans-
fusion-transmitted malaria [27,28]. There are two main as-
pects to keep in mind when considering malaria risk and
transfusion, such as the malaria risk associated with any
individual donor and the ability of the systems to identify
and manage the donor [29]. The development of tests that
are able to screen and identify donors potentially infec-
tious for parasitic infections without causing the deferral
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as one goal for prevention [30]. For this reason, coumarin-
derived dendrimer-based FLISA assay was developed and
compared to conventional ELISA. Because fluorescent
density was highly correlated with parasite numbers,
FLISA is applicable for quantification of parasite numbers
in addition to diagnosis of Plasmodium infection. There-
fore, FLISA has a potential as malarial diagnostic to facili-
tate the accurate diagnosis of Plasmodium infection and it
would be an apparent alternative assay to determine Plas-
modium parasite density. Because fluorescent intensity is
correlated with malaria density with high sensitivity,
FLISA may be considered as a feasible solution for high-
throughput analysis of malaria infection during blood
transfusion in ROK. Further studies should assess the
diagnostic performance for other Plasmodium spp. infec-
tion and asymptomic parasitaemia patients.
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